Trial Profile
A Phase IIa, Double-blind, Randomised, Parallel-group, Multi-centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2423 Compared to Placebo in Patients with Posttraumatic Neuralgia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs AZD 2423 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jan 2012 Additional location (Bulgaria) added as reported by ClinicalTrials.gov.
- 05 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.